

Listing of Claims:

The following listing of claims replaces all previous listings or versions thereof:

1. – 74. (Cancelled)

75. (Previously presented) A method of treating an HIV-infected human subject to reduce the likelihood that said subject will develop AIDS, the method comprising the steps of administering to said subject a pharmaceutically acceptable composition which delivers one or more peptides having peptide sequences selected from the group consisting of one or more of the following groups of peptide sequences:

- a) SEQ ID NO:26, 27, 28, 29, 30, 31, 32, 33 or 34;
- b) SEQ ID NO:20, 21, 22, 23, 24, 25 or 40;
- c) SEQ ID NO:1, 2 or 3;
- d) SEQ ID NO:4, 5, 6, or 7;
- e) SEQ ID NO:8, 9, 10, 11, 12, 13, 14, 15 or 38; and
- f) SEQ ID NO:16, 17, 18, 19 or 20;

wherein the delivery of said peptide(s) promotes the induction of an HIV-directed cytotoxic T-lymphocyte response.

76. (Previously presented) The method of claim 75, further comprising determining whether said subject exhibits an HLA-Cw7-restricted CTL response.

77. (Previously presented) The method of claim 75, wherein the peptides delivered to said subject comprise up to 50 residues.

78. (Previously presented) The method of claim 77, wherein the peptides are 11 to 25 residues in length.

79. (Previously presented) The method of claim 75, wherein the delivered peptides are 11 to 25 residues in length and comprise at least three peptide sequences, wherein at least one peptide sequence is selected from each of the following three groups:

- (a) SEQ ID NO:26, 27, 28, 29, 30, 31, 32, 33 or 34;
- (b) SEQ ID NO:20, 21, 22, 23, 24, 25 or 40; and
- (c) SEQ ID NO:1, 2 or 3.

80. (Previously presented) The method of claim 75, wherein a plurality of peptide sequences are delivered to said subject comprising at least two peptide sequences, one selected from each of the following two groups of peptide sequences:

- (a) SEQ ID NO:26, 27, 28, 29, 30, 31, 32, 33 or 34; or
- (b) SEQ ID NO:1, 2 or 3.

81. (Previously presented) The method of claim 75, wherein a plurality of peptide sequences are delivered to said subject comprising at least two peptide sequences, one selected from each of the following two groups of peptide sequences:

- (a) SEQ ID NO:8, 9, 10, 11, 12, 13, 14, 15 or 38; or
- (b) SEQ ID NO:16, 17, 18, 19 or 39.

82. (Previously presented) The method of claim 80, wherein the plurality of peptide sequences delivered to said subject comprises at least three peptide sequences, one selected from each of the following three groups of peptide sequences:

- (a) SEQ ID NO:26, 27, 28, 29, 30, 31, 32, 33 or 34;
- (b) SEQ ID NO:20, 21, 22, 23, 24, 25 or 40; and
- (c) SEQ ID NO:1, 2 or 3.

83. (Previously presented) The method of claim 82, wherein the plurality of peptide sequences delivered to said subject comprises at least four peptide sequences, one selected from each of the following four groups of peptide sequences:

- (a) SEQ ID NO:26, 27, 28, 29, 30, 31, 32, 33 or 34;
- (b) SEQ ID NO:20, 21, 22, 23, 24, 25 or 40;
- (c) SEQ ID NO:1, 2 or 3; and
- (d) SEQ ID NO:4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 38, 16, 17, 18, 19 or 39.

84. (Previously presented) The method of claim 44, wherein the plurality of peptide sequences delivered to said subject comprises at least five peptide sequences, one selected from each of the following five groups of peptide sequences:

- (a) SEQ ID NO:26, 27, 28, 29, 30, 31, 32, 33 or 34;
- (b) SEQ ID NO:20, 21, 22, 23, 24, 25 or 40;
- (c) SEQ ID NO:1, 2 or 3;
- (d) SEQ ID NO:4, 5, 6 or 7; and
- (e) SEQ ID NO:8, 9, 10, 11, 12, 13, 14, 15, 38, 16, 17, 18, 19 or 39.

85. (Previously presented) The method of claim 84, wherein the plurality of peptide sequences delivered to said subject comprises at least six peptide sequences, one selected from each of the following four groups of peptide sequences:

- (a) SEQ ID NO:26, 27, 28, 29, 30, 31, 32, 33 or 34;
- (b) SEQ ID NO:20, 21, 22, 23, 24, 25 or 40;
- (c) SEQ ID NO:1, 2 or 3;
- (d) SEQ ID NO:4, 5, 6, or 7;
- (e) SEQ ID NO:8, 9, 10, 11, 12, 13, 14, 15 or 38; and
- (f) SEQ ID NO:16, 17, 18, 19 or 20.

86. (Previously presented) The method of claim 75, wherein said peptide(s) are delivered to said subject by means of a viral vector which encodes the peptide(s).

87. (Previously presented) The method of claim 86, wherein the viral vector is selected from the group consisting of vaccinia virus, adenovirus, herpesvirus, retrovirus, adeno-associated virus and lentivirus.

88. (Previously presented) The method of claim 87, wherein the viral vector is adenovirus.

89. (Previously presented) The method of claim 75, wherein said peptide(s) are delivered to said subject by means of a pharmaceutically acceptable composition which comprises the peptide(s).

90. (Previously presented) The method of claim 89, wherein said peptide(s) are coupled to a carrier molecule.

91. (Previously presented) The method of claim 90, wherein said carrier molecule is KLH or BSA.

92. (Previously presented) The method of claim 89, wherein said composition further comprises an adjuvant.

93. (Previously presented) The method of claim 92, wherein said adjuvant is selected from a group consisting of lipids, toxins, cytokines, oligonucleotides and bacterial DNA.

94. (Previously presented) The method of claim 75, further comprising administering AZT to said subject.

95. (Previously presented) The method of claim 75, further comprising carrying out HAART on said subject.

96. (Previously presented) The method of claim 75, wherein the subject does not exhibit an HLA-Cw7-restricted CTL response, further comprising:

- (a) determining if the subject expresses the HLA-Cw7 haplotype; and if so,
- (b) eliciting said response.

97. (Previously presented) The method of claim 96, wherein eliciting said response comprises administering to said subject a therapeutically effective amount of α - or γ -interferon, whereby the level of HLA-Cw7 haplotype expression increases.

98. (Previously presented) The method of claim 75, wherein the composition is injected into the subject intradermally or subcutaneously.

99. (Previously presented) The method of claim 75, wherein the composition is administered more than one time.